Colorectal Cancer Articles

TAS-102 Continues to Demonstrate Efficacy, Safety in CRC and Gastric Cancers
Howard S. Hochster, MD, provides insight into TAS-102 (trifluridine/tipiracil; Lonsurf) and highlights other important research being conducted in the colorectal cancer space.
Study Sheds Light on Incidence Patterns of Early-Onset CRC
Ana Acuna-Villaorduna, MD, provides further insight into the study that compares age and race as factors for the incidence of early-onset colorectal cancer.
Pfizer Acquires Array BioPharma in $11.4 Billion Deal
Pfizer Inc. has entered into a definitive merger agreement with Array BioPharma, in which Pfizer will acquire Array BioPharma for $48 per share in cash, leading to a total enterprise value of an estimated $11.4 billion.
Tumor Sidedness Opens Door for Personalized Therapy in Colorectal Cancer
Sujatha Nallapareddy, MD, discusses how personalized therapy has improved the outlook for patients with colorectal cancer and sheds light on some of the challenges that lie ahead.
Future of mCRC Lies in Biomarker-Directed Therapies
Christopher Lieu, MD, highlights updates on biomarker-directed therapy with colorectal cancer and ongoing research being done with immunotherapy.
Management of Newly Diagnosed mCRC Driven by Molecular Markers
Wells A. Messersmith, MD, discusses the evolving standards of care in colorectal cancer and the importance of molecular testing in guiding treatment decisions.
Laparoscopic Surgery Found to Be Noninferior to Open Surgery Method for CRC Liver Metastases
Similar long-term rates of survival were seen in patients with colorectal cancer and liver metastases regardless of whether the patient underwent laparoscopic or open liver surgery.
Encorafenib, Binimetinib, and Cetuximab Triplet Improves OS, ORR in BRAF+ CRC
The triplet regimen of encorafenib, binimetinib, and cetuximab led to a 48% reduction in the risk of death compared with cetuximab and irinotecan-containing regimens in patients with BRAF V600E-mutant metastatic colorectal cancer who previously received up to 2 lines of therapy, meeting both primary endpoints of the phase III BEACON CRC trial.
Emerging CRC Treatments Highlight Need for Biomarker Testing
With multiple biomarker-directed clinical trials for metastatic CRC expected to produce data within the next few years, experts in gastrointestinal oncology who took part in a recent OncLive Peer Exchange® program recommended that clinicians become more proactive about incorporating genomic and immune markers into their decision making.
Anthony Shields, MD, PhD, shares recent efforts being made with immunotherapy research in colorectal cancer, stressed the importance of molecular testing, and shed light on the use of liquid biopsies in the space.
Publication Bottom Border
Border Publication